Aroa Biosurgery Reaffirms NZ$92-100M Revenue Guidance on CMS Reimbursement Boost
Aroa Biosurgery reaffirms strong FY26 guidance, buoyed by favourable US Medicare reimbursement for Symphony and promising trauma study results for Myriad.
- US CMS sets single outpatient skin substitute reimbursement at US$127.14/cm²
- Symphony Randomised Control Trial completed; publication expected FY27
- Myriad trauma study shows rapid wound coverage with low complications
- FY26 revenue guidance reaffirmed at NZ$92-100 million, EBITDA NZ$5-8 million
- Company confident of upper-end guidance amid sales momentum and reimbursement changes
US Medicare Reimbursement Boosts Symphony’s Market Position
Aroa Biosurgery has received a significant boost from the US Centers for Medicaid and Medicare Services (CMS), which implemented a single reimbursement rate of US$127.14 per square centimetre for outpatient skin substitutes starting January 2026. This pricing framework is expected to streamline the market by phasing out higher-priced competitors, positioning Aroa’s Symphony product favourably for outpatient adoption.
With Symphony responsibly priced, Aroa plans to leverage its existing inpatient hospital relationships to expand into outpatient departments, a strategic move that could accelerate product uptake. While CMS has deferred some proposed changes, such as requiring clinical trial publications for reimbursement, Aroa’s recently completed Symphony Randomised Control Trial (RCT) will provide robust clinical evidence to support future adoption and reimbursement requirements when published in FY27.
Myriad Trauma Study Validates Clinical and Economic Benefits
In parallel, Aroa’s Myriad product has demonstrated compelling clinical outcomes in trauma care. A January study published in The Journal of Trauma & Injury reported that wounds treated with Myriad achieved full vascularised tissue coverage in a median of just 22.5 days, often requiring only a single application and showing no device-related complications. Conducted across four level one trauma centres in the US, the study compared Myriad’s performance favourably against other bioscaffolds, highlighting lower complication and product application rates.
These findings not only reinforce Myriad’s clinical effectiveness but also suggest potential reductions in the total cost of care, a critical factor for hospital decision-makers. The ongoing MASTRR registry study, the largest of its kind for bioscaffolds in complex reconstruction, continues to build a strong evidence base with over 450 patients enrolled and more publications expected in FY27.
Financial Outlook and Market Confidence
Reflecting these operational strengths, Aroa has reaffirmed its FY26 financial guidance, expecting total revenue between NZ$92 million and NZ$100 million and normalised EBITDA of NZ$5 million to NZ$8 million. The company anticipates results will land at the upper end of these ranges, driven by robust direct sales and steady performance of its Ovitex product line.
CEO Brian Ward expressed confidence in closing FY26 strongly, citing favourable reimbursement changes and expanding outpatient opportunities as key growth drivers. Aroa’s direct sales force and partnership with TELABio continue to underpin its distribution strategy in the critical US market.
Looking Ahead
With clinical validation and reimbursement tailwinds aligning, Aroa Biosurgery is poised to deepen its footprint in the competitive soft tissue regeneration market. The upcoming publication of the Symphony RCT and further MASTRR study results will be pivotal in sustaining momentum and unlocking new adoption pathways.
Bottom Line?
Aroa’s clinical progress and reimbursement wins set the stage for a potentially transformative FY27.
Questions in the middle?
- How will competitors respond to the CMS reimbursement rate cap for skin substitutes?
- What market share gains can Symphony realistically achieve in outpatient settings post-RCT publication?
- When will additional MASTRR study results be released, and how might they influence hospital purchasing decisions?
